The COVID-19 pandemic and the Future of Pharmaceutical Manufacturing
- Type: Archived Webinar
- Level: Basic
- Duration: 1 hour
- PDHs: 1.00
The Pharmaceutical industry has changed over the last 20 years. Today, traditional small molecules and biologics coexist with new therapeutic modalities that can offer extremely efficient treatment for common and rare debilitating diseases. Drug substance and drug product complexity could only evolve by the adoption of advanced processing platforms. Efficiency, agility, and flexibility are the major driving forces. The ultra-rapid discovery, development, and manufacturing required to develop treatments for a biological threat such as COVID-19 emphasize that innovations, that seemed to be optional just a year ago, could be immediately deployed. They also reveal major gaps.
This live webinar will review some of the most interesting discussions that took place at AIChE’s PD2M Future of Pharmaceutical Manufacturing workshop last year; and explore the impact that the global pandemic could have on the future of pharmaceutical discovery, development and manufacturing.
Paul Collins is currently a Senior Director in Small Molecule Design and Development at Eli Lilly and Company in Indianapolis. In his current role, Paul has responsibility for product and process development activities for Lilly’s pre-FHD synthetic molecule development portfolio. Prior to this role, he oversaw ongoing efforts for technology platform development, including continuous manufacturing, of both API and drug product.
Paul has also been a Director in Bioprocess Development, Chemical Technology Development, and Chemical Process Development. During his time at Lilly, Paul has...Read more
Joe Hannon is Managing Director of Scale-up Systems Limited, owners and developers of Dynochem software and President of Scale-up Systems Inc. Joe is a chemical engineer and graduated from University College Dublin, Ireland in 1987. He worked first for BHR Group Limited (FMP) in the UK, carrying out laboratory research & development and scale-up work on behalf of a consortium of companies including Dow Chemicals, ICI and DuPont. He obtained his PhD on CFD simulation and prediction of chemical reactions from Cranfield University (UK) in 1992. In 1994 he started Scale-up Systems as a...Read more
Dr. Luciani received her B.S in chemical engineer from Universidad Nacional de Mar del Plata in 2001 and PhD in Chemical Engineering from Universidad Nacional del Litoral in 2006. She spent 4 year at University of Maryland, initially as a postdoctoral fellow and then as a research professor. She joined Small Molecule Design and Development at Eli Lilly in 2011 as a process engineer. In 2014, she joined the process design and development group as the leader of the drug substance M&S group. In that role, she guided a group of chemical engineers and developed models for hybrid and...Read more
|AIChE Member Credits||1|
|AIChE Graduate Student Members||Free|
|AIChE Undergraduate Student Members||Free|
|PD2M Forum Members||Free|